Royalty Pharma plc
RPRXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Royalty Pharma plc (RPRX) is listed under Biotechnology. With a market capitalization of $36.90B, it sits in large-cap territory. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Market Cap
$36.90B
Beta
0.41
P/E (TTM)
33.97
P/E (Fwd)
10.99
EPS (TTM)
$1.88
EPS (Fwd)
$5.81
ROE
14.0%
ROA
5.1%
Cash
$837.0M
Total Debt
$8.96B
Free CF
-$1.20B
52W Change
71.4%
Annual Financials
Cash vs Debt
Where RPRX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, RPRX finished 11.28% above its 150-day moving average ($54.78) and 17.82% above its 200-day moving average ($51.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RPRX overbought or oversold?
At the October 19, 2026 close, RPRX's RSI(14) was 62.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $837.0M in cash, though total debt stands at $8.96B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$1.20B, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 14.0% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $2.24B (2022) to $2.38B (2025).
The relatively low beta of 0.41 suggests RPRX is a less volatile holding compared to the broader index. Royalty Pharma plc carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing RPRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.